Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc.(OTCQX:BIOAF; TSX.V:BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (“BBB”), engages Willow Tree Capital Group of Toronto, Canada. Willow Tree’s full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies worldwide. With its broad transactional experience, Willow Tree specializes in Licensing, strategic consultation and Mergers & Acquisitions services, employing industry-?recognized valuation models for life science market value assessments.
“We are extremely excited to be working with biOasis,” said Cathy Miner, CEO of Willow Tree. “When presented with the opportunity to work with biOasis to find partners for their exciting new technology in the neuroscience field, we soon realized this was a perfect fit for our team. biOasis is currently being presented with a number of opportunities where our team can assist the company and we are looking forward to helping biOasis capitalize on those opportunities that have the potential to address serious unmet medical needs.”
“Engaging Willow Tree is a very strategic decision,” said Rob Hutchison, CEO of biOasis. “Because of the recent advancements that we’ve made with our Transcend Program, interest in biOasis has broadened over the past several months. As we advance key internal and collaborative programs, we recognize that the expertise that Ms. Miner and her team bring to the table can help the biOasis team to maximize the opportunity quotient with respect to our current and future programs.”
About Willow Tree
Willow Tree Capital Group provides strategic advice and assistance with Mergers & Acquisitions, Licensing and Strategic Consulting to life science companies worldwide
biOasis Technologies Inc. is a ground-breaking biopharmaceutical company headquartered in Vancouver, Canada and is focused on the delivery of therapeutic drugs across the blood?brain barrier. The company is developing and commercializing proprietary brain delivery technology platforms to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors Rob Hutchison, Chairman & CEO
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”
biOasis Technologies Inc.
Tiffany Tolmie, 778-383-3280 x103